Skip to navigation bar Skip to breadcrumbs Skip to page content Skip to comments area
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomePublic Comments and NominationsOpportunity for Public CommentDraft Research Plan : Draft Research Plan

Draft Research Plan

Draft Research Plan for Asymptomatic Bacteriuria in Adults: Screening

This opportunity for public comment expires on October 25, 2017 at 8:00 PM EST

Note: This is a Draft Research Plan. This draft is distributed solely for the purpose of receiving public input. It has not been disseminated otherwise by the USPSTF. The final Research Plan will be used to guide a systematic review of the evidence by researchers at an Evidence-based Practice Center. The resulting Evidence Review will form the basis of the USPSTF Recommendation Statement on this topic.

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Send Us Your Comments

In an effort to maintain a high level of transparency in our methods, we open our draft Research Plans to a public comment period before we publish the final version.

Leave a Comment >>

Draft: Proposed Analytic Framework

Figure 1 is the analytic framework that depicts the four Key Questions to be addressed in the systematic review. The figure illustrates how screening asymptomatic pregnant and nonpregant adults may result in reducing the incidence of symptomatic urinary tract infection, kidney infection, and perinatal/maternal morbidity or mortality, as well as improving quality of life (KQ1). Once detected, the figure shows how treatment of asymptomatic bacteriuria may result in improved health outcomes (KQ3). Further, the figure illustrates whether screening for and treatment of asymptomatic bacteriuria are associated with any adverse events (KQ2, KQ4).

Draft: Proposed Key Questions to Be Systematically Reviewed

  1. Does screening for asymptomatic bacteriuria in adults, including pregnant women, improve health outcomes?
  2. What are the harms of screening for asymptomatic bacteriuria?
  3. Does treatment of screen-detected, asymptomatic bacteriuria improve health outcomes?
  4. What are the harms of treatment of screen-detected, asymptomatic bacteriuria?

Draft: Proposed Contextual Questions

Contextual questions will not be systematically reviewed and are not shown in the Analytic Framework.

  1. What is the accuracy of onsite clinical screening tests for asymptomatic bacteriuria?
  2. What is the optimal timing and frequency of screening for asymptomatic bacteriuria in pregnant women?
  3. What is the association between asymptomatic bacteriuria and health outcomes?

Draft: Proposed Research Approach

The Proposed Research Approach identifies the study characteristics and criteria that the Evidence-based Practice Center will use to search for publications and to determine whether identified studies should be included or excluded from the Evidence Review. Criteria are overarching as well as specific to each of the key questions (KQs).

  Included Excluded
Populations KQs 1, 2: Unselected, asymptomatic, community-dwelling adults age ≥18 years (including those residing in independent living facilities)

KQs 3, 4: Community-dwelling adults age ≥18 years with asymptomatic bacteriuria (including those residing in independent living facilities); unselected, asymptomatic pregnant women receiving routine prenatal care (any age)
  • Persons with symptoms of or suspected urinary tract infection (cystitis or pyelonephritis) or with a history of recurrent urinary tract infection
  • Persons who have a compromised immune system
  • Persons who have a catheter, urinary stent, or nephrostomy tube; recipients of a kidney or other organ transplant; patients on kidney dialysis
  • Pregnant women with sickle cell disease
  • Persons seen in specialty care for treatment or follow up of conditions affecting the urinary tract (e.g., prostate cancer)
  • Persons being tested in preparation for urological procedures
  • Persons with spinal cord injuries or who are hospitalized
  • Persons who are institutionalized
Interventions KQs 1, 2: Screening with urine testing (e.g., urine culture, urinalysis with microscopy, dipstick, dipslide, screening with reflex urine culture)

KQs 3, 4: Treatment (e.g., antibiotics) or interventions to prevent urinary tract infection in patients with screen-detected, asymptomatic bacteriuria
Interventions to prevent asymptomatic bacteriuria
Comparisons KQ 1: No screening

KQ 3: No treatment or treatment with a placebo
 
Outcomes KQs 1, 3:
General health outcomes:
  • Urinary tract infection, including cystitis and pyelonephritis
  • Kidney failure
  • Quality of life
  • Mortality
Pregnancy-specific health outcomes:
  • Complications of pregnancy associated with maternal or fetal morbidity: preterm birth (before 37 weeks’ gestation), low birth weight (<2,500 g), preeclampsia, eclampsia, HELLP syndrome, congenital malformations (birth defects)
  • Maternal and fetal/infant mortality
KQs 2, 4: All of the above health outcomes, with attention to fetal anomalies, stillbirth, and adverse effects of treatment with antibiotics (e.g., allergic reactions, secondary infections, and longer-term child health outcomes)
 
Setting Prenatal or primary care settings Hospitals, intermediate care facilities (e.g., nursing home, rehabilitation facility), emergency departments, and other settings not generalizable to primary care
Study Design KQs 1, 3:
Nonpregnant adults: RCTs

Pregnant women*: RCTs, observational cohort studies with a comparator of no screening or no treatment

KQs 2, 4: RCTs, observational cohort studies with and without a comparison group, registry studies
KQs 1, 3:
Nonpregnant adults: Study designs other than RCTs

Pregnant women*: Study designs other than RCTs, observational cohorts with a comparator of no screening or no treatment

KQs 2, 4: Case control studies, case series and case reports, qualitative studies
Countries Nonpregnant adults: Studies conducted in countries categorized as “Very High” on the 2016 Human Development Index (as defined by the United Nations Development Programme)

Pregnant women*: Studies conducted in countries categorized as “Very High” and “High” on the 2016 Human Development Index
Nonpregnant adults: Studies not conducted in countries categorized as “Very High” on the 2016 Human Development Index

Pregnant women*: Studies not conducted in countries categorized as “Very High” or “High” on the 2016 Human Development Index
Publication language English Languages other than English

Abbreviations: HELLP=hemolysis, elevated liver enzymes, low platelet count; RCT=randomized, controlled trial.

*The inclusion criteria for studies of screening for and treatment of asymptomatic bacteriuria in pregnant women are more broad because prior evidence from trials and ensuing recommendations have established a standard practice of screening and treatment.

Current as of: September 2017

Internet Citation: Draft Research Plan: Asymptomatic Bacteriuria in Adults: Screening. U.S. Preventive Services Task Force. September 2017.
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-research-plan/asymptomatic-bacteriuria-in-adults-screening1

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857